FDA Accepts Bristol Myers Squibb (BMY) NDA for Iberdomide With Priority Review

Core Insights - Bristol-Myers Squibb Company (NYSE:BMY) is highlighted as a strong value stock following the FDA's acceptance of its New Drug Application (NDA) for iberdomide, an investigational treatment for relapsed or refractory multiple myeloma [1][3] - The FDA has granted Priority Review and Breakthrough Therapy Designation for iberdomide, with a target action date set for August 17 of this year [1][3] Group 1: Drug Development and Approval - The NDA for iberdomide is supported by data from the Phase 3 EXCALIBER-RRMM trial, which evaluated iberdomide in combination with daratumumab and dexamethasone against a standard three-drug regimen [2] - A significant aspect of the filing is the use of Minimal Residual Disease (MRD) negativity as a primary endpoint, indicating the treatment's effectiveness in clearing the disease and potentially predicting longer remission periods [2] Group 2: Mechanism of Action - Iberdomide operates through targeted protein degradation, tagging specific cancer-promoting proteins for destruction by the cell's internal recycling system [3] - This mechanism builds on Bristol-Myers Squibb's established history with immunomodulatory drugs, aiming to provide a more effective oral treatment option with a manageable safety profile [3]